Anzeige
Mehr »
Login
Donnerstag, 13.05.2021 Börsentäglich über 12.000 News von 658 internationalen Medien
Milliardär und "Starinvestor" verdoppelt jetzt seine Position in einem Pennystock
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
241 Leser
Artikel bewerten:
(1)

Hardman & Co Research: Diurnal (DNL): $52.5m US deal strengthens balance sheet further

Hardman & Co Research 
Hardman & Co Research: Diurnal (DNL): $52.5m US deal strengthens balance sheet 
further 
 
30-March-2020 / 15:05 GMT/BST 
 
Hardman & Co Research: $52.5m US deal strengthens balance sheet further 
 
     Diurnal is a commercial-stage specialty pharmaceutical company focused on 
    diseases of the endocrine system. Its two lead products are targeting rare 
  conditions where medical need is currently unmet, with the aim of building a 
       long-term 'Adrenal Franchise'. Alkindi(R) is currently being rolled out 
  through key European markets and has been submitted to the FDA for approval, 
  with a PDUFA date set at 29 September 2020. Meanwhile, Diurnal has signed an 
    exclusive US commercial deal with Eton Pharmaceuticals, a specialty pharma 
  company focused on hospital and paediatric products. This, together with the 
              recent Placing, has strengthened the balance sheet. 
 
              Please click on the link below for the full report: 
 
https://www.hardmanandco.com/research/corporate-research/52-5m-us-deal-strengt 
hens-balance-sheet-further/ [1] 
 
If you are interested in meeting the company, you can register your interest 
by clicking on the above link. 
 
To contact us:              Contact: 
 
Hardman & Co                Martin Hall      mh@hardmanandco.com 
35 New Broad Street 
London 
EC2M 1NH 
 
                            +44 20 7194 7632 
 
www.hardmanandco.com 
 
Follow us on Twitter 
@HardmanandCo 
 
 Hardman & Co Research can still be accessed for free after MiFID II. Please 
       click here [2] to read the statement. 
 
          About Hardman & Co: For the past 25 years Hardman has been producing 
specialist research designed to improve investors' understanding of companies, 
        sectors, industries and investment securities. Our analysts are highly 
experienced in their sectors, and have often been highly rated by professional 
      investors for their knowledge. Our focus is to raise companies' profiles 
       across the UK and abroad with outstanding research, investor engagement 
 programmes and advisory services. Some of our notes have been commissioned by 
   the company which is the subject of the note; this is clearly stated in the 
              disclaimer where this is the case. 
 
 Hardman Research Ltd, trading as Hardman & Co, is an appointed representative 
        of Capital Markets Strategy Ltd and is authorised and regulated by the 
   Financial Conduct Authority; our FCA registration number is 600843. Hardman 
            Research Ltd is registered at Companies House with number 8256259. 
 
Our research is provided for the use of the professional investment community, 
       market counterparties and sophisticated and high net worth investors as 
  defined in the rules of the regulatory bodies. It is not intended to be made 
  available to unsophisticated retail investors. Anyone who is unsure of their 
   categorisation should consult their professional advisors. This research is 
neither an offer, nor a solicitation, to buy or sell any security. Please read 
              the note for the full disclaimer. 
 
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
End of Announcement - EQS News Service 
 
1010495 30-March-2020 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=a57586daef3c7b4ab65b83748def7fcd&application_id=1010495&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=1010495&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

March 30, 2020 10:05 ET (14:05 GMT)

Kostenloser Wertpapierhandel auf Smartbroker.de
© 2020 Dow Jones News
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.